Stock · SAN.PA · Healthcare
France · Large Cap · Revenue 12 mo. €48B
Price as of 11/06/2026
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions.
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. manufacturing facility in Germany. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Original text from the data provider
Summary
63.3 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €9B (2025), it supports €99.9B. The remaining €459.6M of the market value assume it grows 0.1% a year for 10 years and not at all afterwards.
Required FCF growth per year
0.1%
no growth afterwards
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q1 → Q2 2026
4 more unchanged: Revenue, 12 mo., Gross margin, EBIT margin, Shares outstanding
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 10.95% | 11.52% | Rank 48 |
| Return on capital (Greenblatt) | 67.98% | 32.55% | Rank 82 |
| EBIT margin | 20.54% | 18.31% | Rank 63 |
| FCF margin | 19.24% | 14.12% | Rank 69 |
| Gross margin | 72.07% | 60.99% | Rank 74 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 5.49% | 8.04% | Rank 37 |
| Earnings growth, 3 years per year | −1.31% | 5.44% | Rank 32 |
| Earnings growth, 5 years per year | −8.08% | 7.00% | Rank 12 |
| Sustainable growth (ROE × retained earnings) | 3.77% | 3.66% | Rank 52 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 7.65% | 2.90% | Rank 95 |
| FCF yield | 8.96% | 3.63% | Rank 94 |
| EV/saleslower is better | 2.42 | 4.03 | Rank 69 |
| EV/EBITlower is better | 11.77 | 21.73 | Rank 89 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | −11.79% | 8.66% | Rank 28 |
| Share price, 6 months | 15.04% | 24.27% | Rank 39 |
| Share price, 3 months | 16.33% | 15.42% | Rank 51 |
| Distance from 52-week high | −7.41% | −7.35% | Rank 49 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | −0.38% | 0.30% | Rank 57 |
| Change in share countlower is better | −2.48% | 0.00% | Rank 85 |
| Dividend streak in years | 35 | 10 | Rank 97 |
| Price reaction to results, market-adjusted | 6.32% | 0.05% | Rank 89 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 56.29% | 48.40% | Rank 64 |
| Net debt/EBITDAlower is better | 1.02 | 1.11 | Rank 54 |
| Debt to equitylower is better | 0.28 | 0.48 | Rank 65 |
| Volatility, 1 yearlower is better | 23.47% | 31.42% | Rank 94 |
Ten years in figures
| Year | Revenue, €B | EBIT margin | FCF, €B | Shares | Net debt, €B |
|---|---|---|---|---|---|
| 2016 | 34.7 | 18.8% | 5.8 | 1.29B | 8.3 |
| 2017 | 36.2 | 16.0% | 5.4 | 1.26B | 5.3 |
| 2018 | 35.7 | 13.1% | 3.6 | 1.25B | 17.7 |
| 2019 | 37.6 | 8.1% | 5.9 | 1.25B | 16.2 |
| 2020 | 37.4 | 37.8% | 5.3 | 1.26B | 9.8 |
| 2021 | 39.2 | 20.7% | 8.5 | 1.26B | 12.3 |
| 2022 | 40.3 | 32.6% | 8.3 | 1.26B | 8.5 |
| 2023 | 41.1 | 31.6% | 8.6 | 1.26B | 9.7 |
| 2024 | 44.3 | 32.6% | 5.9 | 1.25B | 10.5 |
| 2025 | 46.7 | 20.5% | 9.0 | 1.22B | 12.9 |
3 of 7 StockScorer Score rules met · How the score is built
Sanofi SA mainly meets criteria in the Valuation category. Result from 18 strategies checked.
Sanofi SA is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
3 of 7 rules met
6 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Sanofi SA.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 13.1 | 30.0 |
| P/B ratio | 1.4 | 4.8 |
| Return on equity (ROE) | 10.9% | 11.5% |
| Equity ratio | 56.3% | 48.4% |
| Debt-to-equity (D/E) | 0.28 | 0.48 |
| Dividend yield | 4.9% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| SAN.PA | Sanofi SAthis page | |
| GSK.L | GSK plc | locked |
| BMY | Bristol-Myers Squibb Company | High7.3 |
| 4519.T | Chugai Pharmaceutical Co. Ltd. | locked |
| BAYN.DE | Bayer AG | locked |
| NOVO-B.CO | Novo Nordisk A/S | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.